Calcitonin Test

Standard thyroid panels check how well your thyroid produces its main hormones. They tell you nothing about a small population of cells tucked inside the thyroid called C cells. These cells do not make thyroid hormone. They make calcitonin, a small protein hormone involved in calcium and bone metabolism. When C cells grow out of control, they become medullary thyroid carcinoma (MTC), a cancer that accounts for roughly 2 to 5 percent of all thyroid cancers. Calcitonin in your blood is the earliest and most reliable signal that something is wrong with those cells.

What makes this test unusual is that the hormone it measures has surprisingly little day-to-day importance in adults. People who have had their entire thyroid removed produce no calcitonin at all, yet their calcium levels and bone health remain stable. Calcitonin's real clinical value is not as a window into calcium balance. It is a tumor marker. And for that purpose, it is among the most powerful tools in oncology: tightly correlated with tumor size, responsive to treatment, and capable of catching disease years before a lump becomes detectable on imaging.

What Calcitonin Tells You

Calcitonin (CT) is made exclusively by the parafollicular C cells of the thyroid. Under normal conditions, these cells release small amounts of calcitonin in response to rising blood calcium levels and after meals (triggered by gut hormones like gastrin). In a healthy person, calcitonin levels are very low, typically under 10 pg/mL.

When calcitonin rises above that range, it raises the question of whether C cells are multiplying. The most concerning cause is medullary thyroid carcinoma. MTC arises directly from C cells, and the tumor produces calcitonin in proportion to its mass. The more tumor, the higher the calcitonin. This tight relationship makes calcitonin both a screening tool and a surveillance marker after treatment.

About 75% of MTC cases are sporadic (no family history). The other 25% are hereditary, caused by inherited mutations in the RET gene. These hereditary forms appear in syndromes called multiple endocrine neoplasia type 2 (MEN2), which can also involve tumors of the adrenal glands and parathyroid glands. In both sporadic and hereditary cases, calcitonin is the primary blood marker for diagnosis, staging, and long-term monitoring.

How Calcitonin Levels Map to Cancer Risk

Men normally have two to four times higher calcitonin levels than women, because they have more C cells. This means the same number on a lab report carries different weight depending on sex. A result of 20 pg/mL in a woman is more concerning than the same result in a man. Research has defined several risk tiers based on basal (unstimulated) calcitonin, and these tiers guide clinical decisions.

These thresholds come from multiple European and North American studies. A 30-year single-center analysis of 306 patients found that only those with calcitonin above 85 pg/mL (women) or 100 pg/mL (men) developed lateral lymph node metastases or distant spread. Patients below those cutoffs had a 95.7% cure rate and 100% disease-specific survival. A separate study of over 29,000 patients confirmed that sex-specific cutoffs of about 8 pg/mL for women and 15 pg/mL for men provided the best balance of sensitivity and specificity for detecting MTC.

Screening and Early Detection

The case for screening rests on a simple fact: catching MTC early changes the outcome dramatically. In a landmark Italian study of 10,864 patients with thyroid nodules, routine calcitonin measurement detected MTC at earlier stages. Among screened patients, 59% achieved complete remission after surgery. Among historical controls who were not screened, only 2.7% did. A Greek study spanning 41 years found the same pattern: after routine calcitonin screening was introduced, tumors were smaller at diagnosis and outcomes improved significantly.

A more recent multicenter study of 149 MTC patients compared those who had preoperative calcitonin screening to those who did not. The screened group had lower recurrence rates (16.1% vs. 36.4%) and lower death rates (0.8% vs. 18.2%). Survival was dramatically better in the screened group, with a hazard ratio of about 18 favoring screening.

Despite these numbers, routine calcitonin screening in all thyroid nodule patients remains debated. A Cochrane review covering over 72,000 patients found that calcitonin has outstanding sensitivity (100%) and specificity (97.2%) at a 10 pg/mL cutoff. But because MTC is rare (occurring in roughly 1 in 250 to 1 in 430 patients with thyroid nodules), even a highly specific test generates many more false positives than true positives. The positive predictive value is only about 7.7%. U.S. guidelines take a neutral position on routine screening, while many European centers screen routinely.

For anyone ordering this test proactively, that context matters. A mildly elevated result is far more likely to be a false positive than a true cancer signal. But a very high result, above 100 pg/mL, is almost always real. The test's value lies in its ability to catch the rare but curable cancer that standard thyroid panels cannot detect at all.

Hereditary Risk and RET Mutations

About one in four MTC cases is caused by an inherited mutation in the RET gene. These mutations cause MEN2 syndromes, where MTC can appear in childhood. For known RET mutation carriers, annual calcitonin monitoring is the standard of care, beginning as early as 6 months of age for the highest-risk mutations. In families with MEN2A, a study of 50 patients found that prophylactic thyroidectomy performed before age 8 resulted in 88% achieving undetectable calcitonin levels after surgery.

If you have a family history of thyroid cancer, especially MTC, or if any family member has been diagnosed with a pheochromocytoma (an adrenal tumor) or hyperparathyroidism at a young age, calcitonin testing and genetic counseling for RET mutations are strongly recommended. Normal calcitonin in a RET mutation carrier can allow doctors to delay surgery and monitor safely, but rising calcitonin signals that it is time to act.

Calcitonin After Treatment: The Prognostic Power of Doubling Time

After surgery for MTC, calcitonin becomes a surveillance tool. Undetectable calcitonin (typically below 2 pg/mL) after total thyroidectomy is the goal and indicates biochemical cure. In one study, patients with truly undetectable postoperative calcitonin had only a 3% recurrence rate, compared to 25% in those whose calcitonin normalized but remained detectable (2 to 10 pg/mL).

When calcitonin remains detectable or starts rising after surgery, the rate of rise matters more than the absolute number. This is measured as calcitonin doubling time: how long it takes for the level to double. A study of 65 MTC patients followed for up to 29.5 years found that doubling time was the single strongest predictor of survival. When calcitonin doubled in less than 6 months, 3 out of 4 patients died during follow-up. When doubling time exceeded 2 years, every patient survived. A meta-analysis of 10 studies confirmed these findings: a calcitonin doubling time under 1 year carried a roughly 22-fold higher risk of death compared to a doubling time over 1 year.

Why a Single Reading Can Be Misleading

Calcitonin has a within-person biological variation (the natural fluctuation from week to week in a healthy person) of about 13%. That means two consecutive readings need to differ by at least 36% to represent a real biological change rather than normal fluctuation. A small rise from 5 to 6 pg/mL is within noise. A jump from 5 to 15 pg/mL is meaningful.

Several common situations can push calcitonin up without any C-cell disease. Proton pump inhibitors (PPIs) like omeprazole are the most frequent medication cause. PPIs raise gastrin levels, and gastrin stimulates C cells to release calcitonin. If you have been on a PPI for more than a couple of months, your calcitonin may be artificially elevated. Kidney disease also raises calcitonin, with 18 to 44% of dialysis patients showing elevated levels. Smoking and high body weight are both associated with modestly higher calcitonin. Beta-blockers and glucocorticoids have also been reported as potential confounders.

Eating before the test can distort results significantly. One study found that postprandial calcitonin levels averaged about 9.5 pg/mL compared to 3.9 pg/mL when fasting, a roughly 2.5-fold difference. Calcitonin also shows some circadian variation, with higher values in the afternoon. For the most reliable result, draw blood in the morning after fasting for several hours.

Acute illness is another major confounder. During sepsis or severe infection, the calcitonin precursor molecule (procalcitonin) rises dramatically and can cross-react with some calcitonin assays. In critically ill patients, mean calcitonin reached 591 pg/mL in one study. Acute trauma elevated calcitonin in 91% of patients at hospital admission. Any calcitonin measurement taken during or shortly after a serious illness or injury should be repeated once you have fully recovered.

Assay Matters: Why You Should Stick with One Lab

Different calcitonin assays can give meaningfully different numbers from the same blood sample. A comparison of three commercial assays found about 13% variation between platforms. Modern automated assays (the types most labs now use) are the most reliable, with very low cross-reactivity to procalcitonin and the ability to detect calcitonin at concentrations as low as about 0.5 to 1.0 pg/mL.

Because of this assay-to-assay variation, serial monitoring should always use the same lab and the same assay platform. Switching labs between measurements can create the appearance of a rise or fall that is actually just a difference in how the test is run. Sample handling also matters: calcitonin degrades if blood sits at room temperature for more than 2 hours or at refrigerator temperature for more than 6 hours. The sample should be processed promptly.

Tracking Your Trend

A single calcitonin reading is a snapshot. Its real power emerges over time. For someone with a normal result and no risk factors, a baseline measurement establishes your starting point. If you have a family history of thyroid cancer or MEN2, annual testing is the standard. For anyone with a mildly elevated result (in the gray zone of roughly 10 to 100 pg/mL), repeating the test in 3 to 6 months at the same lab clarifies whether the elevation is stable (likely benign) or rising (needs investigation).

After treatment for MTC, calcitonin should be measured 2 to 3 months after surgery and then every 6 to 12 months. The trajectory tells the story: falling or undetectable levels indicate cure, stable low-level elevations suggest minimal residual disease that may not require immediate treatment, and rising levels with a short doubling time demand action. No single cutoff matters as much as the direction and speed of the curve.